|
|
 |
|
Viewing report
|
|
|
|
Indevus Pharmaceuticals: Premium Company Profile
Datamonitor, Dec 2007, Pages: 58
Indevus Pharmaceuticals is a biopharmaceutical company focused on obtaining product candidates and product from other pharmaceutical and biotechnology companies through collaboration, in licensing and acquisitions. The companys acquisition of Valera Pharmaceuticals in April 2007 has expanded its product portfolio, establishing it as an emerging leader in the areas of urology and mens health.
Scope of this title
- Contains corporate strategy, value chain presence and SWOT Analysis
- Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors
- Includes information on suppliers/ partners, shareholding structure and key employees with biographies
Highlights of this title
Indevus Pharmaceuticals is a biopharmaceutical company engaged in the acquisition, development and commercialization of products to treat urological, gynecological and mens health conditions.
The companys marketed products are: Sanctura for the treatment of overactive bladder; Delatestryl for treating hypogonadism in men; Supprelin-LA for the treatment of central precocious puberty; and Vantas indicated in hormone suppression therapy for advanced prostate cancer.
Indevus Pharmaceuticals derives its revenues from contract and license fees and product revenues which include revenues from sales of products, commissions and royalties. The company obtains products and product candidates through acquisitions and licensing agreements with other pharmaceutical and biotechnology companies.
Key reasons to purchase this title
- Access all the important information and analysis on the company in a single report
- Understand companys strengths, weaknesses, opportunities and threats along with business strategy and value chain
- Gain access to companys adjusted five year financial data along with key ratios and market capitalization
Customers who bought this item also bought
Indevus Pharmaceuticals, Inc. - Financial and Strategic Analysis Review
Indevus Pharmaceuticals Inc-Therapeutic Competitors
Indevus Pharmaceuticals, Inc.
Financial Markets Research: Indevus Pharmaceuticals Sanctura XR - Last-to-market Entrant Unlikely to Make an Impact in Crowded OAB Market
INDEVUS PHARMACEUTICALS - World'Vest Base Dossier
Indevus Pharmaceuticals Inc.-Therapeutic Competitors
Indevus Pharmaceuticals and Endo Pharmaceuticals Merger Call - - Earnings Transcript
Acquistion Of Indevus Pharmaceuticals, Inc. By Endo Pharmaceuticals Holdings, Inc. Call - Endo Pharmaceuticals Holdings, Inc.,Indevus Pharmaceuticals, Inc., - Earnings Transcript
Indevus Pharmaceuticals Inc.-Financial Company Report
Indevus Pharmaceuticals Inc.-Detailed Product Pipeline
Premium Company Profile Vertex Pharmaceuticals
Premium Company Profile: OSI Pharmaceuticals
|
|
|
|
